Literature DB >> 34915806

Human vaccines & immunotherapeutics: news September 2021.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34915806      PMCID： PMC8973365          DOI： 10.1080/21645515.2021.2007694

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  4 in total

1.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Enriqueta Felip; Nasser Altorki; Caicun Zhou; Tibor Csőszi; Ihor Vynnychenko; Oleksandr Goloborodko; Alexander Luft; Andrey Akopov; Alex Martinez-Marti; Hirotsugu Kenmotsu; Yuh-Min Chen; Antonio Chella; Shunichi Sugawara; David Voong; Fan Wu; Jing Yi; Yu Deng; Mark McCleland; Elizabeth Bennett; Barbara Gitlitz; Heather Wakelee
Journal:  Lancet       Date:  2021-09-20       Impact factor: 79.321

2.  Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.

Authors:  Muhammed O Afolabi; David Ishola; Daniela Manno; Babajide Keshinro; Viki Bockstal; Baimba Rogers; Kwabena Owusu-Kyei; Alimamy Serry-Bangura; Ibrahim Swaray; Brett Lowe; Dickens Kowuor; Frank Baiden; Thomas Mooney; Elizabeth Smout; Brian Köhn; Godfrey T Otieno; Morrison Jusu; Julie Foster; Mohamed Samai; Gibrilla Fadlu Deen; Heidi Larson; Shelley Lees; Neil Goldstein; Katherine E Gallagher; Auguste Gaddah; Dirk Heerwegh; Benoit Callendret; Kerstin Luhn; Cynthia Robinson; Brian Greenwood; Maarten Leyssen; Macaya Douoguih; Bailah Leigh; Deborah Watson-Jones
Journal:  Lancet Infect Dis       Date:  2021-09-13       Impact factor: 71.421

3.  Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

Authors:  David Ishola; Daniela Manno; Muhammed O Afolabi; Babajide Keshinro; Viki Bockstal; Baimba Rogers; Kwabena Owusu-Kyei; Alimamy Serry-Bangura; Ibrahim Swaray; Brett Lowe; Dickens Kowuor; Frank Baiden; Thomas Mooney; Elizabeth Smout; Brian Köhn; Godfrey T Otieno; Morrison Jusu; Julie Foster; Mohamed Samai; Gibrilla Fadlu Deen; Heidi Larson; Shelley Lees; Neil Goldstein; Katherine E Gallagher; Auguste Gaddah; Dirk Heerwegh; Benoit Callendret; Kerstin Luhn; Cynthia Robinson; Maarten Leyssen; Brian Greenwood; Macaya Douoguih; Bailah Leigh; Deborah Watson-Jones
Journal:  Lancet Infect Dis       Date:  2021-09-13       Impact factor: 71.421
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.